20/20 Biolabs (NASDAQ:AIDX) Upgraded by Wall Street Zen to “Hold” Rating

Posted by on Mar 15th, 2026

Wall Street Zen upgraded shares of 20/20 Biolabs (NASDAQ:AIDX – Free Report) to a hold rating in a research report report published on Saturday morning.

20/20 Biolabs Trading Up 2.0%

NASDAQ:AIDX opened at $2.53 on Friday. 20/20 Biolabs has a twelve month low of $2.36 and a twelve month high of $50.00.

20/20 Biolabs Company Profile

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

See Also

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.